AAP
AXSM icon

Arax Advisory Partners’s Axsome Therapeutics AXSM Stock Holding History

Arax Advisory Partners’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$608K Buy
2,485
+2,378
+2,222% +$516K ﹤0.01% 1512
2026
Q1 		$20.7K Sell
107
-87
-45% -$15K ﹤0.01% 2095
2025
Q4 		$35.4K Sell
194
-2,513
-93% -$351K ﹤0.01% 1798
2025
Q3 		$329K Buy
2,707
+2,640
+3,940% +$297K ﹤0.01% 1067
2025
Q2 		$7K Hold
67
– – ﹤0.01% 2117
2025
Q1 		$7.81K Buy
67
+49
+272% +$5.58K ﹤0.01% 1633
2024
Q4 		$1.52K Buy
18
+7
+64% +$644 ﹤0.01% 2075
2024
Q3 		$989 Buy
+11
New +$960 ﹤0.01% 2265

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arax Advisory Partners's AXSM Position: Q2 2026 in Review

Arax Advisory Partners increased its Axsome Therapeutics (AXSM) stake by 2,222% in Q2 2026, buying an estimated $516K and bringing the position to 2,485 shares worth $608K. The position accounts for ﹤0.01% of the portfolio, ranked #1512.

Arax Advisory Partners first reported a position in AXSM in Q3 2024 and has held it in 8 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Arax Advisory Partners held 2,485 shares of Axsome Therapeutics worth $608K as of Q2 2026.
  • Arax Advisory Partners bought 2,378 Axsome Therapeutics shares in Q2 2026, an estimated $516K.
  • Axsome Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #1512 holding.
  • Arax Advisory Partners first reported a position in Axsome Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.